Marianna Mancini - Mar 30, 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Operating Officer
Signature
/s/ Michael Morneau as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Mar 30, 2023
Transactions value $
-$862,045
Form type
4
Date filed
4/3/2023, 07:22 PM
Previous filing
Mar 30, 2023
Next filing
Apr 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $197K +23.1K +8.82% $8.52 285K Mar 30, 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $76.9K +10K +3.51% $7.69 295K Mar 30, 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $19.4K +3K +1.02% $6.47 298K Mar 30, 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise -$614K -36.1K -12.11% $17.01 262K Mar 30, 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +56.7K +21.64% $0.00 319K Mar 30, 2023 Direct F2
transaction VKTX Common Stock, par value $0.00001 per share Tax liability -$541K -30.8K -9.67% $17.57 288K Mar 30, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (right to buy) Options Exercise $0 -23.1K -100% $0.00* 0 Mar 30, 2023 Common Stock 23.1K $8.52 Direct F1, F4
transaction VKTX Stock Option (right to buy) Options Exercise $0 -10K -100% $0.00* 0 Mar 30, 2023 Common Stock 10K $7.69 Direct F1, F5
transaction VKTX Stock Option (right to buy) Options Exercise $0 -3K -75% $0.00 1K Mar 30, 2023 Common Stock 3K $6.47 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals.
F3 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.
F4 25% of the shares subject to the option vested on each one year anniversary of the grant date.
F5 One-third of the shares subject to the option vested on each one year anniversary of the grant date.